Get the Stockscreener App
15.45
0.19%
-0.03
After Hours:
15.45
Travere Therapeutics Inc stock is traded at $15.45, with a volume of 1.12M.
It is down -0.19% in the last 24 hours and up +4.39% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
See More
Previous Close:
$15.48
Open:
$15.19
24h Volume:
1.12M
Relative Volume:
0.72
Market Cap:
$1.37B
Revenue:
$203.45M
Net Income/Loss:
$-351.45M
P/E Ratio:
-3.3956
EPS:
-4.55
Net Cash Flow:
$-369.41M
1W Performance:
-3.13%
1M Performance:
+4.39%
6M Performance:
-24.49%
1Y Performance:
+61.95%
1-Day Range:
$15.16
$15.76
1-Week Range:
$15.16
$16.12
52-Week Range:
$7.931
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
15.45 | 1.37B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
What is Travere Therapeutics Inc. company’s growth strategyTop Growth Data Feed From AI Tools - jammulinksnews.com
Travere Therapeutics to Report Second Quarter 2025 Financial Results - BioSpace
Why Travere Therapeutics Inc. stock attracts strong analyst attentionAccurate Buy Point for Momentum Stocks Detected - beatles.ru
Travere Therapeutics Inc. Matches Institutional Buying FilterDaily Momentum Screener With Alerts Launched - metal.it
Why is Travere Therapeutics Inc. stock attracting strong analyst attentionStock Market Guidance With High Returns - jammulinksnews.com
When is Travere Therapeutics Inc. stock expected to show significant growthLow Risk Alerts Backed By Experts - jammulinksnews.com
What are analysts’ price targets for Travere Therapeutics Inc. in the next 12 monthsReal Time Watchlist To Watch Now - jammulinksnews.com
What are Travere Therapeutics Inc. company’s key revenue driversGet timely alerts on market opportunities - jammulinksnews.com
How does Travere Therapeutics Inc. compare to its industry peersGet alerts on the hottest market movers - jammulinksnews.com
How does Travere Therapeutics Inc. generate profit in a changing economyOutstanding capital returns - jammulinksnews.com
How many analysts rate Travere Therapeutics Inc. as a “Buy”Unlock powerful stock screening for profits - jammulinksnews.com
Is Travere Therapeutics Inc. a good long term investmentRapid portfolio appreciation - PrintWeekIndia
What drives Travere Therapeutics Inc. stock priceExceptional profit potential - PrintWeekIndia
Travere Therapeutics Inc. Stock Analysis and ForecastSuperior portfolio returns - Autocar Professional
What analysts say about Travere Therapeutics Inc. stockTremendous wealth creation - PrintWeekIndia
What analysts say about Travere Therapeutics Inc. stock outlookMassive wealth growth - jammulinksnews.com
Travere Therapeutics, Inc. (NASDAQ:TVTX): Is Breakeven Near? - 富途牛牛
Travere Therapeutics anticipates FILSPARI approval for FSGS by September 2025 - MSN
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):